https://www.thebodypro.com/category/fda-approved-hiv-medications/tag/ias-international-aids-society-conference
FDA-Approved HIV Medications

IAS (International AIDS Society) Conference

The Latest

Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

Christoph D. Spinner

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study Img

Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study

Planned 24-week interim results from a 48-week phase 3 study were presented at IAS 2017 and showed that switching to this fixed-dose combination maintained undetectable viral load.